Amylyx Pharmaceuticals, Inc.

NasdaqGS:AMLX Lagerbericht

Marktkapitalisierung: US$358.8m

Amylyx Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Amylyx Pharmaceuticals CEO ist Josh Cohen , ernannt in Jan 2013, hat eine Amtszeit von 11.83 Jahren. Die jährliche Gesamtvergütung beträgt $7.42M , bestehend aus 8.4% Gehalt und 91.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 4.26% der Aktien des Unternehmens, im Wert von $15.27M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.9 Jahre bzw. 3.8 Jahre.

Wichtige Informationen

Josh Cohen

Geschäftsführender

US$7.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts8.4%
Amtszeit als Geschäftsführer11.8yrs
Eigentum des Geschäftsführers4.3%
Durchschnittliche Amtszeit des Managements3.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.8yrs

Jüngste Management Updates

Recent updates

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Nov 25

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10
Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16
This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16
Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29
We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Josh Cohen im Vergleich zu den Einnahmen von Amylyx Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$259m

Jun 30 2024n/an/a

-US$166m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$7mUS$621k

US$49m

Sep 30 2023n/an/a

US$2m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$149m

Dec 31 2022US$7mUS$539k

-US$198m

Sep 30 2022n/an/a

-US$184m

Jun 30 2022n/an/a

-US$153m

Mar 31 2022n/an/a

-US$121m

Dec 31 2021US$1mUS$418k

-US$88m

Sep 30 2021n/an/a

-US$68m

Dec 31 2020US$671kUS$370k

-US$42m

Vergütung im Vergleich zum Markt: JoshDie Gesamtvergütung ($USD7.42M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.16M).

Entschädigung vs. Einkommen: JoshDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Josh Cohen (32 yo)

11.8yrs

Amtszeit

US$7,418,169

Vergütung

Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Joshua Cohen
Co-Founder11.8yrsUS$7.42m4.26%
$ 15.3m
Justin Klee
Co-Founder11.8yrsUS$7.42m4.2%
$ 15.1m
James Frates
Chief Financial Officer3.8yrsUS$3.51m0.14%
$ 509.8k
Gina Mazzariello
Chief Legal Officer & General Counsel2.8yrsUS$3.01m0.21%
$ 752.4k
Camille Bedrosian
Chief Medical Officerless than a yearUS$2.37m0.030%
$ 108.2k
Tom Holmes
Chief Technical Operations Officerno datakeine Datenkeine Daten
Lindsey Allen
Head of Investor Relations & Communicationsno datakeine Datenkeine Daten
Shauna Horvath
Head of Global Marketing3.9yrskeine Datenkeine Daten
Linda Arsenault
Chief Human Resources Officerless than a yearkeine Datenkeine Daten
Chris Aiello
Head of Canada & GM3.6yrskeine Datenkeine Daten
Keith White
Head of Global Market Access3.9yrskeine Datenkeine Daten
Tammy Sarnelli
Global Head of Regulatory Affairs4.3yrskeine Datenkeine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: AMLXDas Führungsteam des Unternehmens gilt als erfahren (3.9 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Joshua Cohen
Co-Founder10.8yrsUS$7.42m4.26%
$ 15.3m
Justin Klee
Co-Founder10.8yrsUS$7.42m4.2%
$ 15.1m
Peter Finn
Company Secretary & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Walter Gilbert
Special Advisor & Member of Advisory Board3.8yrsUS$51.24kkeine Daten
George Milne
Independent Chairman of the Board9.8yrsUS$385.07k1.26%
$ 4.5m
Rudolph Tanzi
Chairman of The Scientific Advisory Boardno datakeine Datenkeine Daten
Alan Walts
Board Observer & Advisor7.3yrskeine Datenkeine Daten
Karen Firestone
Independent Director1.7yrsUS$681.15k0.081%
$ 289.8k
Daphne Quimi
Independent Director3.4yrsUS$348.59k0.0073%
$ 26.3k
Bernhardt G. Zeiher
Independent Directorless than a yearkeine Datenkeine Daten
Sasha Bakhru
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Paul Fonteyne
Independent Director3.7yrsUS$342.12k0.0058%
$ 20.8k

3.8yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: AMLXDie Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).